radium-223
Jump to navigation
Jump to search
Indications
- advanced prostate cancer, including
* only if prior treatment with docetaxel [NGC, NICE)
Contraindications
- no activity with visceral disease (active only in bone)
Adverse effects
- myelosuppression rates are low
Mechanism of action
- alpha-emitting, bone-seeking, calcium mimetic
- binds into newly formed bone stroma
- alpha-particle radiation induces double-stranded DNA breaks
- short path of alpha particles appears to spare surrounding bone marrow
Notes
- first commercially available targeted alpha therapy
More general terms
Additional terms
References
- ↑ Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013 Jul 18; 369:213 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23863050 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1213755
Vapiwala N and Glatstein E. Fighting prostate cancer with radium-223 - Not your madame's isotope. N Engl J Med 2013 Jul 18; 369:276 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23863055 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1304041